Claims and counterclaims over alleged adverse reaction in covid-19 vaccine in India

The Indian manufacturer of the Oxford-AstraZeneca candidate vaccine against covid-19 (the Serum Institute of India) has threatened to claim Rs1bn (£10m; €11.2m; $13m) in damages from a clinical trial volunteer who alleges he developed a neurological illness after receiving the vaccine and has claimed Rs50m compensation.

Claims and counterclaims over alleged adverse reaction in covid-19 vaccine in India
Size: 140 KB